http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Chapuis, Aude G.,Lee, Sylvia M.,Thompson, John A.,Roberts, Ilana M.,Margolin, Kim A.,Bhatia, Shailender,Sloan, Heather L.,Lai, Ivy,Wagener, Felecia,Shibuya, Kendall,Cao, Jianhong,Wolchok, Jedd D.,Gree The Rockefeller University Press 2016 The Journal of experimental medicine Vol.213 No.7
<P>Adoptive transfer of peripheral blood–derived, melanoma-reactive CD8<SUP>+</SUP> cytotoxic T lymphocytes (CTLs) alone is generally insufficient to eliminate bulky tumors. Similarly, monotherapy with anti-CTLA4 infrequently yields sustained remissions in patients with metastatic melanoma. We postulated that a bolus of enhanced IL-21–primed polyclonal antigen-specific CTL combined with CTLA4 blockade might boost antitumor efficacy. In this first-in-human case study, the combination successfully led to a durable complete remission (CR) in a patient whose disease was refractory to both monoclonal CTL and anti-CTLA4. Long-term persistence and sustained anti-tumor activity of transferred CTL, as well as responses to nontargeted antigens, confirmed mutually beneficial effects of the combined treatment. In this first-in-human study, Chapuis et al. demonstrate that the combination of adoptive cellular therapy with CTLA4 blockade induces long-term remission in a melanoma patient resistant to both modalities administered serially and individually.</P>
INSIGHT INTO THE GROWTH MECHANISM OF WS2 NANOTUBES IN THE SCALED-UP FLUIDIZED-BED REACTOR
R. TENNE,A. ZAK,L. SALLACAN-ECKER,A. MARGOLIN,M. GENUT 성균관대학교(자연과학캠퍼스) 성균나노과학기술원 2009 NANO Vol.4 No.2
The growth mechanism of WS2 nanotubes in the large-scale fluidized-bed reactor is studied in greater detail. This study and careful parameterization of the conditions within the reactor lead to the synthesis of large amounts (50–100 g/batch) of pure nanotubes, which appear as a fluffy powder, and (400–500 g/batch) of nanotubes/nanoplatelets mixture (50:50), where nanotubes usually coming in bundles. The two products are obtained simultaneously in the same reaction but are collected in different zones of the reactor, in a reproducible fashion. The characterization of the nanotubes, which grow catalyst-free, by a number of analytical techniques is reported. The majority of the nanotubes range from 10 to 50 micron in length and 20–180 nm in diameter. The nanotubes reveal highly crystalline order, suggesting very good mechanical behavior with numerous applications.
Thyroid Hormone Augmentation in Treatment-Refractory Depression
Gabriela V Obrocea,Richard A Margolin,Tai P Yoo 대한정신약물학회 2008 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.6 No.1
Objective:Partial response or no response to a single antidepressant trial is not uncommon in the pharmacotherapy of depressive disorders, and resistance to even aggressive treatment regimens, known as treatment-refractory depression (TRD), is an important clinical problem. The additive value of thyroid hormones in this context has been explored over many years, but their utility remains uncertain. The purpose of this paper is therefore to clarify the potential role of thyroid augmentation in treatment-refractory depression, in the light of contemporary pathophysiologic knowledge and the utility of other approaches. Methods:A literature search on thyroid augmentation studies in depression, including TRD, was conducted, using MEDLINE (National Library of Medicine), accessed via the PubMed portal. Results:The review examined the published literature from 1996 to 2005. Several randomized studies and a larger number of uncontrolled investigations which used both Triiodothyronine (T3) and Levothyroxine (T4) in the treatment of affective disorders were identified. Conclusion:The review supports the use of T4 and T3 in TRD, particularly in women suffering from depression and in bipolar depression. While, there is evidence linking thyroid function to affective disorders, the putative mechanisms underlying the action of these hormones in depression suggest promising directions for future research on thyroid treatments for TRD.